133 related articles for article (PubMed ID: 32554277)
21. Structure-activity relationships for a novel series of thiazolyl phenyl ether derivatives exhibiting potent and selective acetyl-CoA carboxylase 2 inhibitory activity.
Clark RF; Zhang T; Xin Z; Liu G; Wang Y; Hansen TM; Wang X; Wang R; Zhang X; Frevert EU; Camp HS; Beutel BA; Sham HL; Gu YG
Bioorg Med Chem Lett; 2006 Dec; 16(23):6078-81. PubMed ID: 16973360
[TBL] [Abstract][Full Text] [Related]
22. Chemical genetics of acetyl-CoA carboxylases.
Zu X; Zhong J; Luo D; Tan J; Zhang Q; Wu Y; Liu J; Cao R; Wen G; Cao D
Molecules; 2013 Jan; 18(2):1704-19. PubMed ID: 23358327
[TBL] [Abstract][Full Text] [Related]
23. Acetyl-CoA carboxylase-a as a novel target for cancer therapy.
Wang C; Rajput S; Watabe K; Liao DF; Cao D
Front Biosci (Schol Ed); 2010 Jan; 2(2):515-26. PubMed ID: 20036965
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor.
Mizojiri R; Nii N; Asano M; Sasaki M; Satoh Y; Yamamoto Y; Sumi H; Maezaki H
Bioorg Med Chem; 2019 Jun; 27(12):2521-2530. PubMed ID: 30879862
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of a monocyclic derivative as a selective ACC1 inhibitor by chemical modification of biphenyl ACC1/2 dual inhibitors.
Mizojiri R; Tomita D; Sasaki M; Satoh Y; Yamamoto Y; Sumi H; Maezaki H
Bioorg Med Chem; 2021 Apr; 35():116056. PubMed ID: 33607488
[TBL] [Abstract][Full Text] [Related]
26. Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats.
Bengtsson C; Blaho S; Saitton DB; Brickmann K; Broddefalk J; Davidsson O; Drmota T; Folmer R; Hallberg K; Hallén S; Hovland R; Isin E; Johannesson P; Kull B; Larsson LO; Löfgren L; Nilsson KE; Noeske T; Oakes N; Plowright AT; Schnecke V; Ståhlberg P; Sörme P; Wan H; Wellner E; Oster L
Bioorg Med Chem; 2011 May; 19(10):3039-53. PubMed ID: 21515056
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.
Nishiura Y; Matsumura A; Kobayashi N; Shimazaki A; Sakamoto S; Kitade N; Tonomura Y; Ino A; Okuno T
Bioorg Med Chem Lett; 2018 Aug; 28(14):2498-2503. PubMed ID: 29903660
[TBL] [Abstract][Full Text] [Related]
28. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Kim CW; Addy C; Kusunoki J; Anderson NN; Deja S; Fu X; Burgess SC; Li C; Ruddy M; Chakravarthy M; Previs S; Milstein S; Fitzgerald K; Kelley DE; Horton JD
Cell Metab; 2017 Aug; 26(2):394-406.e6. PubMed ID: 28768177
[TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity.
Freiberg C; Brunner NA; Schiffer G; Lampe T; Pohlmann J; Brands M; Raabe M; Häbich D; Ziegelbauer K
J Biol Chem; 2004 Jun; 279(25):26066-73. PubMed ID: 15066985
[TBL] [Abstract][Full Text] [Related]
30. Recombinant yeast screen for new inhibitors of human acetyl-CoA carboxylase 2 identifies potential drugs to treat obesity.
Marjanovic J; Chalupska D; Patenode C; Coster A; Arnold E; Ye A; Anesi G; Lu Y; Okun I; Tkachenko S; Haselkorn R; Gornicki P
Proc Natl Acad Sci U S A; 2010 May; 107(20):9093-8. PubMed ID: 20439761
[TBL] [Abstract][Full Text] [Related]
31. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.
Harriman G; Greenwood J; Bhat S; Huang X; Wang R; Paul D; Tong L; Saha AK; Westlin WF; Kapeller R; Harwood HJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):E1796-805. PubMed ID: 26976583
[TBL] [Abstract][Full Text] [Related]
32. Hormonal regulation of acetyl-CoA carboxylase isoenzyme gene transcription.
Zhao LF; Iwasaki Y; Zhe W; Nishiyama M; Taguchi T; Tsugita M; Kambayashi M; Hashimoto K; Terada Y
Endocr J; 2010; 57(4):317-24. PubMed ID: 20139635
[TBL] [Abstract][Full Text] [Related]
33. Expression, purification, and characterization of human acetyl-CoA carboxylase 2.
Kim KW; Yamane H; Zondlo J; Busby J; Wang M
Protein Expr Purif; 2007 May; 53(1):16-23. PubMed ID: 17223360
[TBL] [Abstract][Full Text] [Related]
34. Identification of dual Acetyl-CoA carboxylases 1 and 2 inhibitors by pharmacophore based virtual screening and molecular docking approach.
Bhadauriya A; Dhoke GV; Gangwal RP; Damre MV; Sangamwar AT
Mol Divers; 2013 Feb; 17(1):139-49. PubMed ID: 23334436
[TBL] [Abstract][Full Text] [Related]
35. The identification and pharmacological evaluation of potent, selective and orally available ACC1 inhibitor.
Mizojiri R; Asano M; Sasaki M; Satoh Y; Yamamoto Y; Sumi H; Maezaki H
Bioorg Med Chem Lett; 2019 Dec; 29(23):126749. PubMed ID: 31672259
[TBL] [Abstract][Full Text] [Related]
36. Targeting acetyl-CoA carboxylases: small molecular inhibitors and their therapeutic potential.
Luo DX; Tong DJ; Rajput S; Wang C; Liao DF; Cao D; Maser E
Recent Pat Anticancer Drug Discov; 2012 May; 7(2):168-84. PubMed ID: 22339356
[TBL] [Abstract][Full Text] [Related]
37. Structure-guided inhibitor design for human acetyl-coenzyme A carboxylase by interspecies active site conversion.
Rajamohan F; Marr E; Reyes AR; Landro JA; Anderson MD; Corbett JW; Dirico KJ; Harwood JH; Tu M; Vajdos FF
J Biol Chem; 2011 Dec; 286(48):41510-41519. PubMed ID: 21953464
[TBL] [Abstract][Full Text] [Related]
38. Acetyl-coenzyme A carboxylases: versatile targets for drug discovery.
Tong L; Harwood HJ
J Cell Biochem; 2006 Dec; 99(6):1476-88. PubMed ID: 16983687
[TBL] [Abstract][Full Text] [Related]
39. Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007-2008.
Corbett JW
Expert Opin Ther Pat; 2009 Jul; 19(7):943-56. PubMed ID: 19552511
[TBL] [Abstract][Full Text] [Related]
40. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice.
Gao YS; Qian MY; Wei QQ; Duan XB; Wang SL; Hu HY; Liu J; Pan CY; Zhang SQ; Qi LW; Zhou JP; Zhang HB; Wang LR
Acta Pharmacol Sin; 2020 Mar; 41(3):336-347. PubMed ID: 31645659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
